BTK and myeloid sarcoma: These findings provide directly translatable evidence that oral BTK inhibition indeed has the ability to control disease-associated activation of microglia in MS and that evobrutinib or other BTK inhibitors are promising candidates for the therapeutic targeting of perpetuated MS disease activity driven by CNS-intrinsic inflammatory circuits between CNS-resident cells, for example microglia and CNS-established immune cells [10, 18].